Trevi Therapeutics, Inc.
Haduvio
non-IPF ILD-related chronic cough
Countdown
542days
Phase 2 readout · ~ Dec 31, 2027 estimated
What's at stake
Phase 2 trial results for Haduvio in non-IPF ILD-related chronic cough are due ~ Dec 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“The Company expects topline results from the trial in the second half of 2027.”